Caliway Biopharmaceuticals Co Ltd(TW:6919)
NT$70.00-0.50 (-0.71%)
TW:6919
Caliway Biopharmaceuticals Co Ltd financials statements
NT$70.00
At close:-0.50 (-0.71%)
Caliway Biopharmaceuticals Co Ltd (6919) Ratios
Caliway Biopharmaceuticals Co Ltd Ratios
TW:6919's free cash flow for Q2 2026 was NT$-134.54M. For the 2026 fiscal year, TW:6919's free cash flow was decreased by NT$-5.43M and operating cash flow was NT$-129.10M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 109.71 | 184.02 | 50.81 | 23.41 | 15.26 |
| Quick Ratio | 107.72 | 183.97 | 50.80 | 23.35 | 15.26 |
| Cash Ratio | 17.24 | 130.85 | 46.45 | 13.54 | 15.00 |
| Solvency Ratio | -158.10 | -7.58 | -5.38 | -3.79 | -2.95 |
| Operating Cash Flow Ratio | -293.79 | -9.90 | -5.75 | -5.02 | -2.79 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -94.29 |
| Net Current Asset Value | NT$ 157.01M | NT$ 9.63B | NT$ 3.66B | NT$ 1.06B | NT$ 536.32M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.05 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.06 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Financial Leverage Ratio | 1.01 | 1.01 | 1.02 | 1.06 | 1.11 |
| Debt Service Coverage Ratio | -4337.49 | -2071.20 | -975.06 | -440.58 | -176.71 |
| Interest Coverage Ratio | -4534.35 | -2160.23 | -1031.09 | -478.49 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.01 | 0.02 | 0.03 | 0.04 |
| Net Debt to EBITDA | 0.04 | 10.04 | 7.01 | 2.13 | 2.69 |
| Profitability Margins | |||||
| Gross Profit Margin | 69.72% | 2.83% | 70.56% | -122.68% | 74.83% |
| EBIT Margin | -1859.31% | -1613.95% | -1318.88% | -2493.17% | -1869.95% |
| EBITDA Margin | -1778.58% | -1547.44% | -1247.22% | -2295.67% | -1681.07% |
| Operating Profit Margin | -1859.31% | -1613.95% | -1318.88% | -2493.17% | -1869.95% |
| Pretax Profit Margin | -925.20% | -1325.18% | -1254.64% | -2232.10% | -1817.52% |
| Net Profit Margin | -925.20% | -1325.18% | -1254.64% | -2232.10% | -1817.77% |
| Continuous Operations Profit Margin | -925.20% | -1325.18% | -1254.64% | -2232.10% | -1817.77% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.01% |
| EBT Per EBIT | 49.76% | 82.11% | 95.13% | 89.53% | 97.20% |
| Return on Assets (ROA) | -116.38% | -6.02% | -12.75% | -23.22% | -31.46% |
| Return on Equity (ROE) | -117.17% | -6.06% | -13.04% | -24.59% | -34.79% |
| Return on Capital Employed (ROCE) | -235.02% | -7.37% | -13.67% | -27.00% | -34.27% |
| Return on Invested Capital (ROIC) | -234.94% | -7.36% | -13.63% | -26.81% | -33.86% |
| Return on Tangible Assets | -116.38% | -6.02% | -12.75% | -23.22% | -31.46% |
| Earnings Yield | -0.15% | -0.67% | -2.07% | -3.99% | -3.76% |
| Efficiency Ratios | |||||
| Receivables Turnover | 183.55 | 8.56 | 4.93 | 4.11 | 0.00 |
| Payables Turnover | 285.94 | 44.49 | 6.73 | 11.28 | 9.50 |
| Inventory Turnover | 3.99 | 15.07 | 11.19 | 10.18 | 69.05 |
| Fixed Asset Turnover | 0.75 | 0.72 | 0.48 | 0.13 | 0.12 |
| Asset Turnover | 0.13 | 0.00 | 0.01 | 0.01 | 0.02 |
| Working Capital Turnover Ratio | 0.01 | 0.01 | 0.02 | 0.02 | 0.04 |
| Cash Conversion Cycle | 92.10 | 58.67 | 52.43 | 92.30 | -33.14 |
| Days of Sales Outstanding | 1.99 | 42.65 | 74.08 | 88.80 | 0.00 |
| Days of Inventory Outstanding | 91.39 | 24.22 | 32.61 | 35.85 | 5.29 |
| Days of Payables Outstanding | 1.28 | 8.20 | 54.26 | 32.35 | 38.43 |
| Operating Cycle | 93.38 | 66.87 | 106.70 | 124.66 | 5.29 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.28 | -0.37 | -0.34 | -0.21 | -0.12 |
| Free Cash Flow Per Share | -0.29 | -0.37 | -0.35 | -0.22 | -0.14 |
| Dividend Paid and CapEx Coverage Ratio | -24.85 | -47.11 | -43.75 | -17.14 | -7.43 |
| Capital Expenditure Coverage Ratio | -24.85 | -47.11 | -43.75 | -17.14 | -7.43 |
| Operating Cash Flow Coverage Ratio | -4458.25 | -43.99 | -20.72 | -8.46 | -3.01 |
| Operating Cash Flow to Sales Ratio | -11.22 | -11.77 | -10.90 | -18.92 | -8.97 |
| Free Cash Flow Yield | -0.19% | -0.61% | -1.84% | -3.58% | -2.11% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -673.91 | -150.00 | -48.85 | -25.54 | -26.96 |
| Price-to-Sales (P/S) Ratio | 6298.34 | 1982.08 | 606.94 | 559.71 | 482.91 |
| Price-to-Book (P/B) Ratio | 797.65 | 9.07 | 6.31 | 6.17 | 9.24 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -539.87 | -164.84 | -54.43 | -27.95 | -47.44 |
| Price-to-Operating Cash Flow Ratio | -561.60 | -168.34 | -55.67 | -29.58 | -53.83 |
| Price-to-Earnings Growth (PEG) Ratio | 15.35 | -29.25 | -0.78 | 0.00 | -0.32 |
| Enterprise Value Multiple | -354.08 | -118.05 | -41.65 | -22.25 | -26.04 |
| Enterprise Value | 239.16B | 81.04B | 20.20B | 6.55B | 5.39B |
| EV to EBITDA | -354.08 | -118.05 | -41.65 | -22.25 | -26.04 |
| EV to Sales | 6297.68 | 1826.77 | 519.45 | 510.88 | 437.67 |
| EV to Free Cash Flow | -539.82 | -151.93 | -46.58 | -25.51 | -43.00 |
| EV to Operating Cash Flow | -561.54 | -155.15 | -47.65 | -27.00 | -48.79 |
| Tangible Book Value Per Share | 0.19 | 6.78 | 3.02 | 0.99 | 0.70 |
| Shareholders’ Equity Per Share | 0.19 | 6.78 | 3.02 | 0.99 | 0.70 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Revenue Per Share | 0.02 | 0.03 | 0.03 | 0.01 | 0.01 |
| Net Income Per Share | -0.23 | -0.41 | -0.39 | -0.24 | -0.24 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.50 | 0.82 | 0.95 | 0.90 | 0.97 |
| Research & Development to Revenue | 17.10 | 14.63 | 12.95 | 23.01 | 14.64 |
| SG&A to Revenue | 2.19 | 2.20 | 0.95 | 2.67 | 4.81 |
| Stock-Based Compensation to Revenue | 3.22 | 1.47 | 0.59 | 1.54 | 6.06 |
| Income Quality | 1.21 | 0.89 | 0.87 | 0.85 | 0.49 |
Currency in TWD
